Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Stage-specific sensitivity to p53 restoration during lung cancer progression

Nature volume 468, pages 572–575 (2010)Cite this article

Subjects

Abstract

Tumorigenesis is a multistep process that results from the sequential accumulation of mutations in key oncogene and tumour suppressor pathways. Personalized cancer therapy that is based on targeting these underlying genetic abnormalities presupposes that sustained inactivation of tumour suppressors and activation of oncogenes is essential in advanced cancers. Mutations in the p53 tumour-suppressor pathway are common in human cancer and significant efforts towards pharmaceutical reactivation of defective p53 pathways are underway1,2,3. Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas. We define amplification of MAPK signalling as a critical determinant of malignant progression and also a stimulator of Arf tumour-suppressor expression. The response to p53 restoration in this context is critically dependent on the expression of Arf. We propose that p53 not only limits malignant progression by suppressing the acquisition of alterations that lead to tumour progression, but also, in the context of p53 restoration, responds to increased oncogenic signalling to mediate tumour regression. Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development. These data suggest that restoration of pathways important in tumour progression, as opposed to initiation, may lead to incomplete tumour regression due to the stage-heterogeneity of tumour cell populations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Lung adenomas are apathetic to Trp53 restoration, whereas adenocarcinomas are responsive.
Figure 2: Adenocarcinoma cells are sensitive to Trp53 restoration and are specifically eliminated from lung tumours.
Figure 3: Adenocarcinomas are typified by amplified MAPK signalling.
Figure 4: Arf is specifically expressed in adenocarcinomas and sensitizes lung cancer cells to Trp53 restoration.

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    Article  CAS  Google Scholar 

  2. Selivanova, G. & Wiman, K. G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243–2254 (2007)

    Article  CAS  Google Scholar 

  3. Wang, W. & El-Deiry, W. S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20, 90–96 (2008)

    Article  Google Scholar 

  4. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007)

    Article  CAS  Google Scholar 

  5. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006)

    Article  CAS  Google Scholar 

  6. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo . Nature 445, 661–665 (2007)

    Article  CAS  Google Scholar 

  7. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a . Cell 88, 593–602 (1997)

    Article  CAS  Google Scholar 

  8. Palmero, I., Pantoja, C. & Serrano, M. p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125–126 (1998)

    Article  ADS  CAS  Google Scholar 

  9. Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008–3019 (1998)

    Article  CAS  Google Scholar 

  10. Tuveson, D. A. et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375–387 (2004)

    Article  CAS  Google Scholar 

  11. Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genet. 40, 600–608 (2008)

    Article  CAS  Google Scholar 

  12. Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493–505 (2007)

    Article  CAS  Google Scholar 

  13. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras . Genes Dev. 15, 3243–3248 (2001)

    Article  CAS  Google Scholar 

  14. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001)

    Article  ADS  CAS  Google Scholar 

  15. Quintanilla, M., Brown, K., Ramsden, M. & Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322, 78–80 (1986)

    Article  ADS  CAS  Google Scholar 

  16. Bremner, R. & Balmain, A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61, 407–417 (1990)

    Article  CAS  Google Scholar 

  17. Liu, M. L. et al. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17, 2403–2411 (1998)

    Article  CAS  Google Scholar 

  18. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours Nature doi:10.1038/nature09526. (this issue)

    Article  ADS  CAS  Google Scholar 

  19. Young, N. P. & Jacks, T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107, 10184–10189 (2010)

    Article  ADS  CAS  Google Scholar 

  20. Lane, D. P. p53, guardian of the genome. Nature 358, 15–16 (1992)

    Article  ADS  CAS  Google Scholar 

  21. Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104–107 (2009)

    Article  ADS  CAS  Google Scholar 

  22. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289–1295 (2005)

    Article  CAS  Google Scholar 

  23. Bolstad, B. M., Collin, F., Simpson, K. M., Irizarry, R. A. & Speed, T. P. Experimental design and low-level analysis of microarray data. Int. Rev. Neurobiol. 60, 25–58 (2004)

    Article  CAS  Google Scholar 

  24. Bolstad, B. M., Irizarry, R. A., Gautier, L. & Wu, Z. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R., Carey, V., Huber, W., Irizarry, R. & Dudoit, S. ) Ch. 2, 13–32 (Springer, 2005)

    Book  Google Scholar 

  25. Smyth, G. K., Michaud, J. & Scott, H. S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067–2075 (2005)

    Article  CAS  Google Scholar 

  26. Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540–1542 (2006)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank M. DuPage and C. Kim for critical reading of the manuscript. We are indebted to D. Crowley, E. Vasile and M. Griffin at the Koch Institute Core facilities (supported by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute). We are grateful to M. Luo for microarray support. We thank M. Leversha at MSKCC for FISH. D.M.F. has been supported by the American Cancer Society (New England Area Fellow), and is a current Fellow of the Leukemia and Lymphoma Society. K.K.K. is supported by the John Reed Fund of the MIT undergraduate research program. M.M.W. was a Merck Fellow of the Damon Runyon Cancer Research Foundation and a Genentech postdoctoral fellow. T.J. is the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. The Howard Hughes Medical Institute supported this work.

Author information

Authors and Affiliations

  1. Department of Biology, Koch Institute for Integrative Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, 02139, Massachusetts, USA

    David M. Feldser, Kamena K. Kostova, Monte M. Winslow, Sarah E. Taylor, Chris Cashman, Charles A. Whittaker, Francisco J. Sanchez-Rivera, Rebecca Resnick, Michael T. Hemann & Tyler Jacks

  2. Tufts University, and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, 02115, Massachusetts, USA

    Roderick Bronson

Authors
  1. David M. Feldser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamena K. Kostova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monte M. Winslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah E. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chris Cashman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles A. Whittaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francisco J. Sanchez-Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rebecca Resnick
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roderick Bronson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael T. Hemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tyler Jacks
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.M.F. and T.J. conceived of the experiments and wrote the manuscript with comments from all authors; D.M.F., K.K.K, C.C., S.E.T. and R.R. performed the experiments and analysed the data; M.M.W. and F.J.S.-R. gave conceptual advice; R.B. performed histological evaluations; C.A.W. performed bioinformatics data analysis; and M.T.H. provided reagents and conceptual advice.

Corresponding author

Correspondence to Tyler Jacks.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

Gene expression data was deposited in Gene Expression Omnibus (GSE23875).

Supplementary information

Supplementary Figures

The file contains Supplementary Figures 1-9 with legends. (PDF 2225 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldser, D., Kostova, K., Winslow, M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010). https://doi.org/10.1038/nature09535

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature09535

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer